Period
|
Grant title
|
Source
|
2023-2025 |
Cannabis use in pregnancy; effects on endocrine and immune functions of the placenta (GACR 23-07094S) |
GACR |
2022-2025
|
National Institute for Neurological Research
|
EXCELES
|
2022-2025
|
Effects of gestational diabetes on placental inflammasome
|
AZV
|
2022-2024
|
Impact of maternal immune activation on serotonergic system in the fetoplacental unit and fetal, juvenile and adult neurodevelopment (GACR 22-08045S)
|
GACR
|
2022-2024
|
Use of cannabis in pregnancy; effect on placental functions
|
GAUK
|
2021-2023
|
Pregnancy disorders; effect on fetal development and programming
|
START
|
2021-2023
|
Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta
|
GAUK
|
2019-2022 |
Engineering a novel cell-based model for assessing materno-fetal drug transfer during pregnancy (OC-2019-019)
|
Swiss 3R Competence Centre |
2020-2024
|
Placental tryptophan metabolism linking maternal inflammation and foetal neurodevelopmental disorders (AZV NU20-01-00264)
|
AZV
|
2020-2023
|
Antidepressants in pregnancy; effect on placental transport and metabolism of serotonin (GACR 20-13017S)
|
GACR
|
2019-2021
|
Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta
|
GAUK
|
2017-2019
|
In vitro, in situ and ex vivo study of interactions of novel antiviral agents with drug transporters; effect on their passage across the placenta (GACR 17-16169S)
|
GACR
|
2016-2018
|
Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy (GACR 16-26849S)
|
GACR
|
2012-2016
|
Transplacental pharmacokinetics of antiretroviral drugs; interactions with drug efflux transporters (P303/12/0850)
|
GACR
|
2012-2014
|
Study of interaction of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter (700912 C 2012)
|
GAUK
|
2012-2014
|
Study of transplacental pharmacokinetics of antiretroviral drugs emtricitabine, tenofovir and tenofovir disoproxil fumarate; interactions with drug-efflux transporters (695912 C 2012)
|
GAUK
|
2010-2012
|
Localization and function of Organic Cation Transporter 3 (OTC3) in the Rat Placenta (114510 C 2009)
|
GAUK
|
2009-2011
|
Interactions of Breast Cancer Resistance Protein (BCRP/ABCG2) and Purine Cyclin-dependent Kinase Inhibitors In Vitro and In Situ (114909 C 2009)
|
GAUK
|
2007-2009
|
Role of efflux transporters in the placenta for fetus protection and detoxication (119007 C 2007)
|
GAUK
|
2007-2009
|
Regulation mechanisms of drug elimination during hepatic injury (116807 C 2007)
|
GAUK
|
2006-2008
|
Expression and function of BCRP in the placenta at different stages of gestation (103/2006 C)
|
GAUK
|
2006-2007
|
Expression and function of 11β-HSD2 in the placenta in vitro and in vivo (102/2006 C)
|
GAUK
|
2005-2008
|
In-vitro study of molecular-genetic cause of cell resistance against selected drugs (1A8696-4/2005)
|
IGA
|
2005-2007
|
Cytochrome P450 3A4 and multidrug resistance proteins MDR1 and MRP2 as main cause of drug interaction during elimination of drugs from organism (092/2005/C/LFHK)
|
GAUK
|
2005-2006
|
Study of interactions of antiepileptic drugs with efflux transporters (BCRP, MRP2 and P-glycoprotein) in vitro (94/2005/C/FaF)
|
GAUK
|
2005
|
RNA interference in transepithelial transport studies (753/2005)
|
FRVŠ
|
2004-2006
|
Investigation of drug efflux transporters using RNA interference and transfected cell lines (151/2004/C/FaF)
|
GAUK
|
2004
|
Building laboratories of molecular pharmacology (908/2004)
|
FRVŠ
|
2004
|
Visualization of placental membrane transporters using fluorescence microscopy (38p17)
|
AKTION
|